According to Drummond’s FHIR Testing Market Study, over 51% of organizations never test post-release. This matters because the healthcare IT landscape does not pause. Payers update their FHIR servers. Providers shift their coding infrastructure. Health information exchanges add endpoints. Without continuous validation, integrations that worked on launch day start failing silently months later. Organizations discover these failures in production, not in testing, and the cost of that discovery is exponential (increased engineering time to diagnose, longer remediation cycles, customer calls, and operational disruption).
These are fortunately all avoidable. A simple test would have caught the degradation weeks earlier. But most organizations rely on pre-launch connectathons and validation, treating launch day as the finish line instead of the start of an ongoing problem.
The difference between controlling remediation costs and having them control you comes down to one choice: treating interoperability as a continuous requirement instead of a one-time launch event. Most organizations treat launch day as the finish line. The ones that don’t (the ones that build testing into their workflow) rarely face the production failures their peers do.
Why Pre-Launch Testing Cannot Predict Production Behavior
Connectathons bring developers together for intensive, multi-party testing under controlled conditions. The value of that collaboration is real. The gap is found in what connectathons cannot do.
According to the market study, over 54% of health IT developers do not attend connectathons at all. Among those who participate, almost 67% report that connectathons alone do not adequately prepare them for production deployment. Connectathons test conformance to a specification snapshot at a defined moment. What they cannot test is how systems behave when partners interpret the same implementation guide differently, how they handle vendor-specific optional fields, or what undocumented behaviors real-world partners have embedded into production systems over years of use.
The logical next step would be continuous post-launch validation. Most organizations recognize this need. Few are able to sustain it. Understanding why requires looking at what prevents organizations from maintaining testing after go-live.
The Barriers to Continuous Testing
Testing post-launch is not optional. Organizations managing real-world integrations know this. Yet maintaining it requires resources and coordination most do not have. When surveyed about barriers to continuous testing, participants identified three consistent obstacles. Time and access to testing partners are the most common, each cited by 50% of participants. Cost follows at approximately 43%.
Healthcare organizations experience these barriers most acutely. Among healthcare organizations surveyed, approximately 58% cited both time and cost as barriers. This reflects a structural constraint: testing competes with core clinical and administrative work for limited resources.
The problem is not that organizations are choosing to abandon testing. The problem is that they lack the time, the partners, and the resources to maintain it. For organizations managing dozens or hundreds of integrations, the logistics become prohibitive without external infrastructure that handles partner coordination and continuous validation.
FHIRplace addresses this by absorbing the orchestration that overwhelms internal teams. It maintains live connections to production partners, eliminating the coordination burden. It manages partner matching and baseline validation continuously, so organizations maintain testing without building new infrastructure internally. That operational feasibility is what makes continuous validation sustainable for those who recognize the need but lack the means.
But removing the operational barrier is only the first half of the argument. The second half is what happens when you don’t.
The Cost of Discovering Problems in Production
Fixing a defect in production costs exponentially more than fixing it during testing. The Consortium for Information and Software Quality estimates the cost of poor software quality in the US at $2.41 trillion annually, including operational failures, unsuccessful projects, and accumulated technical debt.
This matters because of a paradox. Among organizations surveyed in the FHIR Testing study, approximately 67% identified partner readiness as their number one interoperability risk. Yet approximately 51% stop testing after go-live, leaving partner readiness unvalidated precisely when it matters most.
The financial impact spans multiple dimensions. A developer who finds an issue during controlled testing knows which partner, which scenario, and which data pattern caused it. A developer discovering the same issue because patients are experiencing service disruption must reverse-engineer the failure from production logs, coordinate with a customer in crisis mode, defend the fix through an emergency change process, and manage clinical risk that far exceeds the technical remediation cost. In healthcare, this extends beyond engineering.
A prior authorization integration failure that slows claim processing by one day costs thousands in operational overhead. An integration that breaks silently until a patient is denied care creates organizational liability that dwarfs any pre-launch testing investment. The financial math is straightforward. An incompatibility caught during continuous validation costs hours to fix. The same incompatibility discovered in production costs thousands or millions.
What Actually Works
Continuous validation does not mean testing every change, every day. It means maintaining baseline validation across your partner network that surfaces incompatibilities as they emerge, not after they break patient care.
This requires three things: structured environments for testing, access to actual partner systems instead of mocks, and continuous baseline validation that surfaces issues before production. FHIRplace absorbs the barriers that cause most organizations to stop testing. It manages partner matching and coordination. It provides ongoing access to real production partners, not reference implementations or lab environments. It operates continuously throughout the development lifecycle, not as a one-time event.
Organizations that test continuously find problems on their timeline. Organizations that stop testing find them on their partners’ timeline, in their production environments, with their patients waiting. The infrastructure you build now determines which organization you are.
Drummond’s FHIR Testing Market Study surveyed developers and health IT leaders across the sector. The full report includes additional findings on testing frequency by organization type, validation practice differences between developers and integrators, and specific barriers to testing methods. Download the report here to see the full findings.